


RealRate

PHARMACEUTICAL 2020

Pfenex Inc. Rank 28 of 362





PHARMACEUTICAL 2020



Pfenex Inc. Rank 28 of 362

The relative strengths and weaknesses of Pfenex Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pfenex Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 423% points. The greatest weakness of Pfenex Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 172%, being 475% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	63,760
Cost of Goods Sold	4,891
Intangible Assets	9,310
Liabilities, Current	9,666
Liabilities, Non-Current	26
Other Assets	4,073
Other Compr. Net Income	0
Other Expenses	1.0
Other Liabilities	2,896
Other Net Income	235
Property and Equipment	7,744
Research and Development	25,533
Revenues	50,326
Selling, General and Administrative Expense	19,078

Output Variable	Value in 1000 USD
Assets	84,887
Liabilities	12,588
Expenses	49,503
Stockholders Equity	72,299
Net Income	1,058
Comprehensive Net Income	1,058
Economic Capital Ratio	172%